---
title: Design of a phase III, double-blind, randomised, placebo-controlled trial of
  BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)
date: '2023-09-14'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37709661/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230915181246&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'INTRODUCTION: Progressive pulmonary fibrosis (PPF) includes any diagnosis
  of progressive fibrotic interstitial lung disease (ILD) other than idiopathic pulmonary
  fibrosis (IPF). However, disease progression appears comparable between PPF and
  IPF, suggesting a similar underlying pathology relating to pulmonary fibrosis. Following
  positive results in a phase II study in IPF, this phase III study will investigate
  the efficacy and safety of BI 1015550 in patients with PPF ...'
disable_comments: true
---
INTRODUCTION: Progressive pulmonary fibrosis (PPF) includes any diagnosis of progressive fibrotic interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF). However, disease progression appears comparable between PPF and IPF, suggesting a similar underlying pathology relating to pulmonary fibrosis. Following positive results in a phase II study in IPF, this phase III study will investigate the efficacy and safety of BI 1015550 in patients with PPF ...